Antisense oligodeoxyribonucleotides targeted to the epidermal growth factor (EGF) receptor 
ered into cultured KB cells via folate receptor-mediated endocytosis. The oligonucleotides were a phosphodiester 15 mer antisense to the EGF receptor (EGFR) gene stop codon (AEGFR2), the same sequence with three phosphorothioate linkages at each terminus (AEGFR2S), a randomized 15-mer control of similar base composition to AEGFR2 (RC15), a 14-mer control derived from a symmetrized Escherichia coil lac operator (LACM), and the 5'-fluorescein-labeled homologs of several of the above. Cellular uptake of AEGFR2 encapsulated in folate-PEG-liposomes was nine times higher than AEGFR2 encapsulated in nontargeted liposomes and 16 times higher than unencapsulated AEGFR2. Treatment of KB cells with AEGFR2 in folate-PEG-liposomes resulted in growth inhibition and significant morphological changes. Curiously, AEGFR2 and AEGFR2S encapsulated in folate-PEGliposomes exhibited virtually identical growth inhibitory effects, reducing KB cell proliferation by >90% 48 hr after the cells were treated for 4 hr with 3 ,iM oligonucleotide. Free AEGFR2 caused almost no growth inhibition, whereas free AEGFR2S was only one-fifth as potent as the folate-PEGliposome-encapsulated oligonucleotide. Growth inhibition of the oligonucleotide-treated cells was probably due to reduced EGFR expression because indirect immunofluorescence staining of the cells with a monoclonal antibody against the EGFR showed an almost quantitative reduction of the EGFR in cells treated with folate-PEG-liposome-entrapped AEGFR2. These results suggest that antisense oligonucleotide encapsulation in folate-PEG-liposomes promise efficient and tumorspecific delivery and that phosphorothioate oligonucleotides appear to offer no major advantage over native phosphodiester DNA when delivered by this route.
Antisense oligodeoxyribonucleotides have shown great efficacy in the selective inhibition of gene expression (1) (2) (3) (4) . However, the therapeutic applications of such antisense oligonucleotides are currently limited by their low physiological stability, slow cellular uptake, and lack of tissue specificity. The instability obstacles have been largely overcome by use of backbone-modified oligonucleotides that are more resistant to nucleases. Methylphosphonates, protein-nucleic acid conjugates, and phosphorothioates all appear to resist enzymatic digestion better than the corresponding natural oligonucleotides (5) (6) (7) (8) .
Problems with cellular uptake of antisense oligonucleotides have been more difficult to solve. Endogenous uptake pathways that rely on pinocytosis and related processes generally
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have insufficient capacity to deliver the quantities of antisense of oligonucleotides required to suppress gene expression (9) . Hydrophobic modifications have also been undertaken to improve membrane permeability, but such derivatization strategies are most useful only for short oligonucleotides (9) . Although complexes of antisense constructs with cationic liposomes (10, 11) and polylysine (12, 13) have significantly enhanced intracellular delivery, they have simultaneously introduced new disadvantages of their own. Thus, both methods exhibit some carrier cytotoxicity, and like other protocols, neither strategy allows for any tissue or cell targeting. In short, intracellular delivery and tissue specificity remain major obstacles to the implementation of antisense drugs in the treatment of human disorders.
We have observed that the vitamin folic acid can be used to deliver macromolecules into the cytoplasm of cells expressing a folate receptor. When folate is linked to a macromolecule via its 'y-carboxylate moiety, the affinity of folate for its cellsurface receptor remains essentially unaltered (Kd 10-9 M) (14) (15) (16) (17) (18) (19) . Importantly, folate has already been exploited to nondestructively deliver antibodies, toxins, enzymes, small organic molecules, genes, and liposomes into receptor-bearing cells (14) (15) (16) (17) (18) (19) . We report here that folate-PEG-liposomes can deliver sufficient antisense against the growth factor receptor (EGFR) into KB cells to eliminate EGFR expression, to alter cell morphology (20) , and to halt cell growth. Importantly, at similar concentrations, the free antisense oligonucleotides exhibit little effect. 24 hr to '50% confluence unless stated otherwise.
MATERIALS AND METHODS
Design of the Oligonucleotides. The AEGFR2 oligonucleotide sequence, 5'-CCGTGGTCATGCTCC-3', is complementary to positions 3811-3825 of the EGFR cDNA (21), which contains the opal translation termination codon at residues 3817-3819. Incorporation of three phosphorothioate linkages at each terminus gave AEGFR2S (5'-CsCsGsTGGTCATGCsTsCsC-3'). The corresponding oligonucleotides bearing a 5'-fluorescein phosphoramidite gave fluorescein-AEGFR2 and fluorescein-AEGFR2S. Two control oligonucleotides were used, a phosphodiester 14-mer based on a symmetrized E. coli lac operator with the sequence 5'-TGTGTGCGCACACA-3' (LACM), and a randomized phosphodiester 15-mer oligonucleotide with the sequence 5'-GCTGACGCACTGACT-3' (RC15).
Synthesis of the Oligonucleotides. The 5'-O-DMT-2'-deoxyribonucleoside-3'-O-linked solid-phase supports were prepared from long-chain alkylamine controlled-pore glass using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and the appropriate 5'-O-DMT-2'-deoxyribonucleoside-3'-0-succinates (22) and packed into Pharmacia cassettes. All DNA sequences were synthesized by the solid-phase phosphoramidite method (23) on a Pharmacia GeneAssembler synthesizer, with the phosphodiester oligonucleotides synthesized according to the manufacturer's protocols. The phosphorothioate linkages in AEGFR2S and fluorescein-AEGFR2S were generated via sulfurization of the terminal P(III) to P(V) with the Beaucage reagent (24) in acetonitrile. The 5'-fluorescein-labeled sequences were synthesized by using the fluorescein phosphoramidite, yielding a 1:1 fluorescein/oligonucleotide stoichiometry. The finished sequences were cleaved from the support and deprotected with concentrated NH40H at 60°C for 14 hr. Each deprotection mixture was then chromatographed in reversed-phase mode on a 7 x 305-mm Hamilton PRP-1 column with a linear gradient of 30 mM (pH 7.2) triethylammonium acetate and acetonitrile. The pooled tritylated fractions were lyophilized, detritylated in 20% acetic acid at 55°C for 1 hr, relyophilized, and then rechromatographed on the same column. The pooled DNA fractions were lyophilized to dryness and then relyophilized from 2 ml of 10 mM NaPi at pH 7.4. The samples were stored at -5°C until use. The fluorescein-labeled oligonucleotides were chromatographed once, lyophilized to dryness, and then relyophilized from 2 ml of 10 mM NaPi at pH 7.4 and stored at -5°C until use.
Encapsulation of Antisense Oligonucleotides in Liposomes. Liposomes encapsulating the antisense oligonucleotides were prepared by the extrusion method (25) . Briefly, 50 mg of egg phosphatidylcholine and 16.5 mg of cholesterol (giving a molar ratio of 3:2) were dissolved in 3 ml of chloroform. For folate-targeted liposomes, 5 mg (0.5 mol%) of folate-PEGdistearoylphosphatidylethanolamine, synthesized as described (19) 
RESULTS
Uptake of Free and Encapsulated Oligonucleotides by Cultured KB Cells. Cellular uptake of the various oligonucleotide formulations is illustrated in Fig. 1 . After incubation at 37°C for 4 hr, uptake of the free 5'-labeled phosphodiester species, fluorescein-AEGFR2, was barely detectable (bar a), whereas 1.3 x 106 molecules of the free exonuclease-resistant analog (fluorescein-AEGFR2S, bearing the 5' and 3' phosphorothioate linkages) were internalized by the KB cells under similar conditions (bar b). The uptake of oligonucleotides was greatly enhanced by liposome encapsulation and folate targeting. Approximately 2.1 X 107 molecules of folate-PEG-liposomeencapsulated fluorescein-AEGFR2 entered each cell, an amount exceeding uptake of the free fluorescein-AEGFR2S by -#16-fold (bar d). The cellular uptake of fluorescein-AEGFR2 was also enhanced by encapsulation in nontargeted liposomes (bar c), presumably due to the protective effect of the liposomal membrane against nuclease digestion. Still, the level of uptake was only one-ninth of that for the folatetargeted oligonucleotides. The uptake of folate-PEGliposome-encapsulated oligonucleotides could be competitively inhibited by 1 mM free folic acid, indicating the cellular delivery is mediated by folate receptors (bar e).
Intracellular Distribution of Folate-PEG-LiposomeEncapsulated Oligonucleotides. The intracellular distribution of fluorescein-labeled folate-PEG-liposome-encapsulated antisense oligonucleotides was examined by confocal fluorescence microscopy. After 4-hr incubation at 37°C, oligonucleotides were distributed primarily on the cell surface and within endocytic vesicles (data not shown). However, by 24-hr incu- bation at 37°C, the fluorescein-labeled oligonucleotides were observed throughout the cytosol, with some enrichment in the nucleus. The kinetics of these uptake events corresponds closely to that seen for other liposome-encapsulated material (18) .
Effect of Liposome-Encapsulated Oligonucleotides on KB Cell Proliferation. The growth and morphology of KB cells treated with various oligonucleotide formulations were examined under the phase-contrast microscope. Fig. 2 Lower displays KB cells that were grown for 48 hr in fresh medium after 4-hr exposure to antisense oligonucleotides. KB cells treated with folate-PEG-liposome-encapsulated AEGFR2 (data not shown) or AEGFR2S (Lower Left) developed a fibroblast-like morphology with a much lower cell density than observed for the untreated controls. However, cells treated with free AE-GFR2 or AEGFR2S (data not shown) remained similar in appearance to the untreated cells (Lower Right). As shown in Fig. 3 , treatment of KB cells with folate-PEG-liposomeencapsulated AEGFR2 resulted in an "90% reduction in proliferation compared with untreated cells, whereas free AEGFR2 had almost no effect on growth inhibition. Folate-PEG-liposome-encapsulated AEGFR2S, the more nucleaseresistant oligonucleotide, showed roughly the same efficacy (92% inhibition) as the folate-PEG-liposome-entrapped unmodified oligonucleotide, whereas free AEGFR2S caused a 15% growth inhibition. AEGFR2 encapsulated in nontargeted liposomes (lacking folate) also inhibited growth but was only '20% as effective. Oligonucleotide-free folate-PEG-liposomes had virtually no growth inhibitory effect. Finally, to demonstrate the sequence specificity of these effects, two control folate-PEG-liposome-encapsulated oligonucleotides (RC15 and LACM) were also delivered into KB cells, but both oligonucleotides showed very little growth inhibitory potency.
To evaluate the long-term effect of antisense delivery on KB cell proliferation, KB cells were treated for 4 hr with antisense oligonucleotides and then transferred to fresh medium for up to 10 days. Fig. 4 shows that maximal growth inhibition by folate-PEG-liposome-encapsulated AEGFR2 or AEGFR2S occurred during the first 4 days after treatment, and then the cellular growth rate returned to normal. The duration of growth inhibition by encapsulated AEGFR2S was slightly greater than AEGFR2, but otherwise no difference was seen. Free AEGFR2S was almost ineffective, and treatment with free AEGFR2 exerted no effect at all (data not shown). untreated cultures revealed a high distribution of EGFR throughout the cell. The free antisense constructs and two control oligonucleotides entrapped in folate-PEG-liposomes gave qualitatively similar results to the untreated cells (data not shown).
DISCUSSION
We have compared the cellular uptake of free antisense oligonucleotides with the same antisense constructs encapsulated in nontargeted and folate receptor-targeted liposomes. The latter liposome formulation was found to promote internalization of nine times more oligonucleotide than its nontargeted counterpart and 16 times more than the free oligonucleotide. Because the functional assay-i.e., inhibition of cell growth, suppression of EGFR expression, and induction of fibroblast morphology (20)-also reflected the same relative potencies, we conclude that the folate-PEG-liposome antisense is delivered intracellularly in functionally active form.
Importantly, this conclusion agrees with previous data (14, 19) , showing that folate endocytosis does not culminate in lysosome deposition but rather leads to nondestructive release of much of the internalized material into the cytosol.
Deprivation of growth stimuli for several days can often induce a cell to undergo apoptosis. Unfortunately, our antisense-mediated suppression of EGFR expression inhibited cell proliferation for only 4 Because of the sensitivity of native phosphodiester DNA to nucleases, significant effort has been devoted to developing more stable oligonucleotide backbone chemistries (5) (6) (7) (8) . In our study, however, folate-PEG-liposome-encapsulated phosphodiester and phosphorothioate oligonucleotides showed essentially identical potencies up to 4 days after treatment (Figs.  3 and 4) . These similar inhibitory potencies may have arisen because release or escape of the antisense oligonucleotide from the internalized liposomes may be rate-limiting in oligo-nucleotide degradation. Although discovery of methylphosphonates, phosphorothioates, and protein-nucleic acid constructs have greatly improved antisense stability, problems with cytotoxicity, enantiomeric purity, and cost have prompted researchers to continue their search for the ideal backbone chemistry. Obviously, a single study should not be extrapolated to apply to all antisense research, but if differences between targeted liposomal formulations of chemically different oligonucleotides continue to prove negligible, then the emphasis in antisense research may more appropriately be focused on delivery instead of stability.
Overexpression of the EGFR has been observed in a variety of human cancers and may be related to cell transformation (20, 27) . Recent studies also show that many cancers overexpress a high-affinity receptor for folic acid on their cell surfaces (28) (29) (30) (31) (32) (33) . Although the conjugation of folic acid to an antisense oligonucleotide should permit its cell-specific targeting, we feel the folate-PEG-liposome formulation offers several advantages not shared by the isolated oligonucleotide. (i) As noted above, the protection provided by the liposomal membrane may obviate the need for unnatural backbone chemistries. (ii) Because of its carrying capacity, the targeted liposome can deliver multiple antisense constructs at each receptor or receptor cluster, thereby enhancing the quantity of antisense delivered. (iii) The liposome should retard loss of the antisense through the kidneys and avoid rapid degradation by extracellular nucleases. (iv) Because of its potential for multiple attachments to adjacent receptors, folate-PEGliposomes can avoid significant competition from endogenous folates (18, 19) . Although other means of liposome targeting are also possible, folate represents an attractive candidate because the ligand is inexpensive, compatible with either organic or aqueous solvents, easy to conjugate to PEG and other liposome tethers, and relatively specific for many human tumors.
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